Oncternal Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 30
- Market Cap
- -
- Website
- http://www.oncternal.com
- Introduction
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Target Recruit Count
- 59
- Registration Number
- NCT05917470
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸XCancer Omaha, Omaha, Nebraska, United States
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
- Conditions
- Relapsed/Refractory Aggressive B-Cell Malignancies
- Interventions
- Drug: Bridging Therapy
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Target Recruit Count
- 57
- Registration Number
- NCT05588440
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Lymphatic DiseasesImmunoproliferative DisordersLymphoma, Mantle-CellImmune System DiseasesLymphoma, Non-HodgkinLymphomaLymphoproliferative DisordersLymphoma, B-Cell
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Registration Number
- NCT05431179
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
- Conditions
- B-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMarginal Zone LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Target Recruit Count
- 95
- Registration Number
- NCT03088878
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Sanford Stem Cell Clinical Center at UCSD, La Jolla, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Target Recruit Count
- 85
- Registration Number
- NCT02657005
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States